IMMUNOTECH-B (06978) announced that on February 9, 2026, the company, investors, and other relevant parties entered into a subscription agreement. The company conditionally agreed to issue, and the investors conditionally agreed to subscribe for, new convertible bonds with a principal amount of RMB 270 million. The initial conversion price is set at HKD 2.92 per share. Additionally, notes with a principal amount of RMB 30 million will be issued. The proceeds from the subscription are designated specifically for the full and final settlement of the principal amount of the 2023 convertible bonds, which are due on February 20, 2026. Both the new convertible bonds and the notes will benefit from the security constituted by the mortgage documents. Based on the initial conversion price of HKD 2.92 per share (equivalent to RMB 2.62), the full exercise of the conversion rights attached to the new convertible bonds would result in the allotment and issuance of up to 103 million new shares. This represents approximately 16.66% of the currently issued share capital and about 14.28% of the issued share capital as enlarged by the allotment and issuance of the conversion shares. Upon receipt of the new convertible bonds and notes, and provided the company has paid the accrued but unpaid interest on the 2023 convertible bonds and fulfilled the conditions specified therein, the investors are to execute a discharge deed in favor of the company to confirm the full and final settlement of the 2023 convertible bonds.